Systemic Catabolism of Alzheimer's Aβ40 and Aβ42
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
To better understand the physiologic excretion and/or catabolism of circulating peripheral amyloid beta (Abeta), we labeled human Abeta40 (monomeric, with predominant unordered structure) and Abeta42 (mixture of monomers and oligomers in approximately 50:50 ratio, rich in beta-sheet conformation) with either Na(125)I or (125)I-tyramine cellobiose, also known as the cell-trapping ligand procedure, testing their blood clearance and organ uptake in B6SJLF1/J mice. Irrespective of the labeling protocol, the peptide conformation, and the degree of oligomerization, both Abeta40 and Abeta42 showed a short half-life of 2.5-3.0 min. The liver was the major organ responsible for plasma clearance, accounting for >60% of the peptide uptake, followed by the kidney. In vivo, hepatocytes captured >90% of the radiolabeled peptides which, after endocytosis, were preferentially catabolized and excreted into the bile. Biliary excretion of intact as well as partially degraded Abeta species became obviously relevant at doses above 10 microg. The use of biotin-labeled Abeta allowed the visualization of the interaction with HepG2 cells in culture, whereas competitive inhibition experiments with unlabeled Abeta demonstrated the specificity of the binding. The capability of the liver to uptake, catabolize, and excrete large doses of Abeta, several orders of magnitude above its physiologic concentration, may explain not only the femtomolar plasma levels of Abeta but the little fluctuation observed with age and disease stages.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The rapid degradation of Aβ in the periphery (t1/2 = 2–3 min) precludes a direct and sensitive measurement of the rate of Aβ appearance from brain into blood (27, 28).”
From Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis (2012) · cites this paper as [27]
In the citing paper
“The rapid degradation of Aβ once it enters the blood from brain precludes direct and reliable measurement of its influx rate by conventional means (27, 28).”
From Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis (2012) · cites this paper as [27]
In the citing paper
“The liver clears approximately 60% of circulating Aβ.226”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [226]
Citations
Cites
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Neurodegenerative diseases and oxidative stress
Barnham, K. J., Masters, C. L., & Bush, A. I. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1330 · Cited by 3,683
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease
Lue, L.-F., Kuo, Y.-M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., & Rogers, J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65184-x · Cited by 1,530
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447
Self-citationShibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Self-citationTargeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?
Klein, W. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01749-5 · Cited by 989
Basic and Clinical Pharmacology
Wingard, L. B. (1983) · Anesthesia & Analgesia · doi:10.1213/00000539-198308000-00015 · Cited by 630
Water-soluble Aβ(N-40, N-42) oligomers in normal and Alzheimer disease brains
Kuo, Y.-M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J., & Roher, A. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.8.4077 · Cited by 618
Metalloenzyme-like Activity of Alzheimer's Disease β-Amyloid
Opazo, C., Huang, X., Cherny, R. A., Moir, R. D., Roher, A. E., White, A. R., Cappai, R., Masters, C. L., Tanzi, R. E., Inestrosa, N. C., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206428200 · Cited by 579
Evolution of amyloid: What normal protein folding may tell us about fibrillogenesis and disease
Lansbury, P. T. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3342 · Cited by 553
Wang, H.-W., Pasternak, J. F., Kuo, H., Ristic, H., Lambert, M. P., Chromy, B., Viola, K. L., Klein, W. L., Stine, W. B., Krafft, G. A., et al. (2002) · Brain Research · doi:10.1016/s0006-8993(01)03058-x · Cited by 527
Roher, A. E., Chaney, M. O., Kuo, Y.-M., Webster, S. D., Stine, W. B., Haverkamp, L. J., Woods, A. S., Cotter, R. J., Tuohy, J. M., Krafft, G. A., et al. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20631 · Cited by 498
Volles, M. J., & Lansbury, P. T. (2002) · Biochemistry · doi:10.1021/bi0121353 · Cited by 487
Näslund, J., Schierhorn, A., Hellman, U., Lannfelt, L., Roses, A. D., Tjernberg, L. O., Silberring, J., Gandy, S. E., Winblad, B., & Greengard, P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8378 · Cited by 468
Self-citationAmyloid-β immunotherapy for Alzheimer's disease: the end of the beginning
Schenk, D. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn938 · Cited by 436
Volles, M. J., & Lansbury, P. T. (2003) · Biochemistry · doi:10.1021/bi030086j · Cited by 433
Zlokovic, B. V., Martel, C. L., Matsubara, E., McComb, J. G., Zheng, G., McCluskey, R. T., Frangione, B., & Ghiso, J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4229 · Cited by 430
Self-citationRapid Communication: Characterization of β‐Amyloid Peptide from Human Cerebrospinal Fluid
Vigo‐Pelfrey, C., Lee, D., Keim, P., Lieberburg, I., & Schenk, D. B. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb09841.x · Cited by 385
Oda, T., Wals, P., Osterburg, H. H., Johnson, S. A., Pasinetti, G. M., Morgan, T. E., Rozovsky, I., Stine, W. B., Snyder, S. W., Holzman, T. F., et al. (1995) · Experimental Neurology · doi:10.1006/exnr.1995.1080 · Cited by 352
Vaccination with soluble Aβ oligomers generates toxicity‐neutralizing antibodies
Lambert, M. P., Viola, K. L., Chromy, B. A., Chang, L., Morgan, T. E., Yu, J., Venton, D. L., Krafft, G. A., Finch, C. E., & Klein, W. L. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00592.x · Cited by 349
Presence of soluble amyloid β–peptide precedes amyloid plaque formation in Down's syndrome
Teller, J. K., Russo, C., Debusk, L. M., Angelini, G., Zaccheo, D., Dagna-Bricarelli, F., Scartezzini, P., Bertolini, S., Mann, D. M. A., Tabaton, M., et al. (1996) · Nature Medicine · doi:10.1038/nm0196-93 · Cited by 328
Pittman, R. C., Carew, T. E., Glass, C. K., Green, S. R., Taylor, C. A., & Attie, A. D. (1983) · Biochemical Journal · doi:10.1042/bj2120791 · Cited by 318
Farris, W., Mansourian, S., Leissring, M. A., Eckman, E. A., Bertram, L., Eckman, C. B., Tanzi, R. E., & Selkoe, D. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63229-4 · Cited by 269
β‐Amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?
Carson, J. A., & Turner, A. J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00855.x · Cited by 261
Mackic, J. B., Stins, M., McComb, J. G., Calero, M., Ghiso, J., Kim, K. S., Yan, S. D., Stern, D., Schmidt, A. M., Frangione, B., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2029 · Cited by 242
Self-citationTissue sites of degradation of apoprotein A-I in the rat.
Glass, C. K., Pittman, R. C., Keller, G. A., & Steinberg, D. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)32346-9 · Cited by 241
Ghersi‐Egea, J. ‐., Gorevic, P. D., Ghiso, J., Frangione, B., Patlak, C. S., & Fenstermacher, J. D. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67020880.x · Cited by 222
Self-citationBarnham, K. J., Ciccotosto, G. D., Tickler, A. K., Ali, F. E., Smith, D. G., Williamson, N. A., Lam, Y.-H., Carrington, D., Tew, D., Kocak, G., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305494200 · Cited by 190
Insulin-degrading enzyme: embarking on amyloid destruction
Kurochkin, I. V. (2001) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(01)01876-x · Cited by 177
Amyloidosis and Alzheimer’s disease
Ghiso, J., & Frangione, B. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00149-7 · Cited by 158
Self-citationTHE HALF-LIFE OF HOMOLOGOUS GAMMA GLOBULIN (ANTIBODY) IN SEVERAL SPECIES
Dixon, F. J., Talmage, D. W., Maurer, P. H., & Deichmiller, M. (1952) · Journal of Experimental Medicine · doi:10.1084/jem.96.4.313 · Cited by 158
Characterization of Apolipoprotein J-Alzheimer's Aβ Interaction
Matsubara, E., Frangione, B., & Ghiso, J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7563 · Cited by 153
Self-citationButterfield, D. A., & Bush, A. I. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.027 · Cited by 145
Ghiso, J., Rostagno, A., Gardella, J. E., Liem, L., Gorevic, P. D., & Frangione, B. (1992) · Biochemical Journal · doi:10.1042/bj2881053 · Cited by 132
Self-citationSoluble Amyloid β-Protein Is a Marker of Alzheimer Amyloid in Brain But Not in Cerebrospinal Fluid
Tabaton, M., Nunzi, M. G., Xue, R., Usiak, M., AUTILIO‐GAMBETTI, L., & Gambetti, P. L. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1634 · Cited by 126
Catabolism of human tissue plasminogen activator in mice
Fuchs, H., Berger, H. J., & Pizzo, S. (1985) · Blood · doi:10.1182/blood.v65.3.539.539 · Cited by 113
Molecular regulation of copper excretion in the liver
Wijmenga, C., & Klomp, L. W. J. (2004) · Proceedings of the Nutrition Society · doi:10.1079/pns2003316 · Cited by 107
Oligomerization and fibril assembly of the amyloid-β protein
Roher, A. E., Baudry, J. Y., Chaney, M. O., Kuo, Y., Stine, W. B., & Emmerling, M. R. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00030-2 · Cited by 106
Amyloid-beta peptide, substance P, and bombesin bind to the serpin-enzyme complex receptor.
Joslin, G., Krause, J. E., Hershey, A. D., Adams, S., Fallon, R. J., & Perlmutter, D. H. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)54721-9 · Cited by 103
Protofibrils, the unifying toxic molecule of neurodegenerative disorders?
Haass, C., & Steiner, H. (2001) · Nature Neuroscience · doi:10.1038/nn0901-859 · Cited by 98
Functional and structural properties of lipid-associated apolipoprotein J (clusterin)
CALERO, M., TOKUDA, T., ROSTAGNO, A., KUMAR, A., ZLOKOVIC, B., FRANGIONE, B., & GHISO, J. (1999) · Biochemical Journal · doi:10.1042/bj3440375 · Cited by 98
Self-citationAlzheimer's soluble amyloid β is a normal component of human urine
Ghiso, J. A., Calero, M., Matsubara, E., Governale, S., Chuba, J. V., Beavis, R. C., Wısnıewskı, T., & Frangione, B. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00400-6 · Cited by 98
Self-citationThe α5β1 Integrin Mediates Elimination of Amyloid-β Peptide and Protects Against Apoptosis
Matter, M. L., Zhang, Z., Nordstedt, C., & Ruoslahti, E. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.141.4.1019 · Cited by 98
Receptor-Mediated Transport of Human Amyloid β-Protein 1–40 and 1–42 at the Blood–Brain Barrier
Poduslo, J. F., Curran, G. L., Sanyal, B., & Selkoe, D. J. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0238 · Cited by 94
Clearance of Tissue Plasminogen Activator by Mannose and Galactose Receptors in the Liver
Smedsrød, B. H., & Einarsson, M. (1990) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1645687 · Cited by 94
Boland, K., Behrens, M., Choi, D., Manias, K., & Perlmutter, D. H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.30.18032 · Cited by 89
Morelli, L., Llovera, R. E., González, S. A., Affranchino, J. L., Prelli, F., Frangione, B., Ghiso, J. A., & Castaño, E. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300276200 · Cited by 88
Self-citationPlasma transthyretin. Tissue sites of degradation and turnover in the rat.
Makover, A., Moriwaki, H., Ramakrishnan, R., Saraiva, M. J., Blaner, W. S., & Goodman, D. S. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68346-2 · Cited by 85
Hutchinson, W. L., Noble, G., Hawkins, P. N., & Pepys, M. B. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117474 · Cited by 85
Liver takes up retinol-binding protein from plasma.
Gjøen, T., Bjerkelund, T., Blomhoff, H. K., Norum, K. R., Berg, T., & Blomhoff, R. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)60905-6 · Cited by 76
Vascular disorder in Alzheimer’s disease: role in pathogenesis of dementia and therapeutic targets
Zloković, B. V. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00150-3 · Cited by 73
Holtzman, D. M., Bales, K. R., Paul, S. M., & Demattos, R. B. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00158-8 · Cited by 70
Poduslo, J. F., Curran, G. L., Haggard, J. J., Biere, A. L., & Selkoe, D. J. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0132 · Cited by 52
A safer vaccine for Alzheimer’s disease?
Sigurdsson, E. M., Wısnıewskı, T., & Frangione, B. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00124-0 · Cited by 52
Self-citationBoland, K. A., Manias, K., & Perlmutter, D. H. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.47.28022 · Cited by 51
Retinol-binding Protein and Asialo-orosomucoid Are Taken Up by Different Pathways in Liver Cells
Malaba, L. C., Smeland, S., Senoo, H., Norum, K. R., Berg, T., Blomhoff, R., & Kindberg, G. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.26.15686 · Cited by 44
Quantitative aspects of the uptake and degradation of lysozyme in the rat kidney in vivo
Hysing, J., & Tolleshaug, H. (1986) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(86)90120-5 · Cited by 35
Morelli, L., Llovera, R. E., Ibendahl, S., & Castaño, E. M. (2002) · Neurochemical Research · doi:10.1023/a:1021679817756 · Cited by 27
Kindberg, G. M., Gudmundsen, O., & Berg, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38802-7 · Cited by 26
Maekawa, H., & Tollefsen, D. M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.31.18604 · Cited by 26
Studies of the in vivo synthesis and catabolism of serum amyloid P component (SAP) in the mouse.
Baltz, M. L., Dyck, R. F., & Pepys, M. B. (1985) · PubMed · Cited by 20
Perlmutter, D. H. (1994) · Pediatric Research · doi:10.1203/00006450-199409000-00001 · Cited by 16
Immunization for Alzheimer's disease
Sigurdsson, E. M., Frangione, B., & Wısnıewskı, T. (2002) · Drug Development Research · doi:10.1002/ddr.10068 · Cited by 14
Self-citationClearance of Desialylated Mouse α-Macroglobulin and Murinoglobulin in the Mouse
Abe, K., Yamamoto, K., & Sinohara, H. (1990) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a123272 · Cited by 2
(1999) · doi:10.1002/1531-8249(199912)46:6<860::aid-ana8>3.0.co;2-m
Research works printed but not linked: 5
- Seglen, 1993, Methods Toxicol., 1, 231
- Friedman, 1993, Methods Toxicol., 1, 292
- Baltz, 1985, Clin. Exp. Immunol., 59, 235
- Authier, 1996, Clin. Investig. Med., 19, 149
- Hone, 2003, J. Alz. Dis., 5, 1
Cited by
A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain
Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808
Blood–Brain Barrier Dysfunction as a Cause and Consequence of Alzheimer's Disease
Erickson, M. A., & Banks, W. A. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.135 · Cited by 572
The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia: Two Roads Converged
Craft, S. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.27 · Cited by 547
Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease
Roher, A. E., Esh, C. L., Kokjohn, T. A., Castaño, E. M., Van Vickle, G. D., Kalback, W. M., Patton, R. L., Luehrs, D. C., Daugs, I. D., Kuo, Y., et al. (2009) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2008.10.004 · Cited by 414
Craft, S. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.08.021 · Cited by 348
Metadata
- Authors
- Ghiso, J., Shayo, M., Calero, M., Ng, D., Tomidokoro, Y., Gandy, S., Rostagno, A., & Frangione, B.
- Affiliations
- New York University (US)
- Instituto de Salud Carlos III (ES)
- Corresponding author
- Ghiso, Jorge
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-10
- Volume
- 279
- Issue
- 44
- Pages
- 45897-45908
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2062647232
- Cited by
- 209
- References
- 68
- Citations by year
- 2026: 13 · 2025: 15 · 2024: 18 · 2023: 5 · 2022: 9 · 2021: 19 · 2020: 15 · 2019: 8 · 2018: 6 · 2017: 8 · 2016: 7 · 2015: 8 · 2014: 8 · 2013: 11 · 2012: 11
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5832 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P01AG010491, AG10491, R01AG008721, AG-08721, AG05891)
- National Institute of Neurological Disorders and Stroke (NS 38777, R01NS038777)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- amyloid-beta, Aβ40, amyloid-beta 42, plasma clearance, hepatic uptake, biliary excretion, hepatocytes, peptide oligomerization, peptide conformation, beta-sheet, endocytosis, HepG2 cells, Alzheimer's disease
- MeSH terms
- Amino Acid Sequence, Animals, Bile, Humans, Iodine Radioisotopes, Liver, Male, Molecular Sequence Data, Tissue Distribution, Amyloid beta-Peptides, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.